Anodyne Nanotech, a Scale Up 3 Cohort member, is a venture-backed biotech company based in Boston, developing transdermal forms of breakthrough medicines. Their flagship product, the Hero Patch, utilizes patented microneedle technology to deliver biologic drugs effectively and painlessly, eliminating the need for traditional injections. By focusing on optimizing and streamlining drug delivery systems, Anodyne aims to enhance patient outcomes and improve overall health. The company has established early collaborations with leading pharmaceutical partners to advance its mission and leverage new technology. With a commitment to transforming how medicines are delivered, Anodyne Nanotech is paving the way for a new era in healthcare.

Anodyne Nanotech appointed Jeff Mihm as a member of their Board of Directors, bringing in another level of expertise to the company. Mr. Mihm played an integral role in the $428 million sale of Noven to Hisamitsu Pharmaceuticals and brings a wealth of experience and expertise in the pharmaceutical industry. Additionally, Anodyne Nanotech raised $2.5M, led by Big Pi Ventures, to further develop its innovative patented technology, the Hero Patch.

Anodyne in Three:

What problem is Anodyne solving? Anodyne is solving the problem of painful and inconvenient drug delivery by providing a painless, more efficient delivery method for biologic therapies.

What’s innovative about Anodyne? The company’s Hero Patch technology enables the transdermal delivery of biologics, replacing traditional injections with a painless, non-invasive solution.

Who is Anodyne’s Board of Directors? C-level executives, large pharmaceutical companies, serial biotech entrepreneurs and others.